Anti-Hypertensive Drugs - Czechia

Czechia

Highlights

The Anti-Hypertensive Drugs market in Czechia is expected to generate a revenue of US$41.34m in 2024.
It is projected to experience a moderate annual growth rate (CAGR 2024-2029) of -0.05%, leading to a market volume of US$41.24m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$12.29bn in 2024.
The demand for anti-hypertensive drugs in Czechia is increasing due to the rising prevalence of hypertension in the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Czechia has been experiencing steady growth over the past few years, driven by several factors.

Customer preferences: Czechia has an aging population, which has led to an increase in the prevalence of hypertension. As a result, there is a growing demand for anti-hypertensive drugs in the country. Additionally, there is a trend towards self-medication among Czech consumers, which has further boosted the sales of over-the-counter anti-hypertensive drugs.

Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in Czechia is the increasing use of combination therapies. This trend is being driven by the fact that combination therapies are more effective in controlling blood pressure than monotherapies. Furthermore, there is a growing preference for fixed-dose combination therapies, which simplify the treatment regimen for patients.Another trend in the market is the increasing use of generic drugs. This trend is being driven by the fact that generic drugs are more affordable than their branded counterparts. Furthermore, the government has been promoting the use of generic drugs in the country as a cost-saving measure.

Local special circumstances: One of the unique aspects of the Anti-Hypertensive Drugs market in Czechia is the high level of regulation. The Czech government regulates the prices of drugs, which has led to lower prices for consumers. However, this has also led to lower profit margins for pharmaceutical companies operating in the country.

Underlying macroeconomic factors: The Czech economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has benefited the Anti-Hypertensive Drugs market, as more resources are being allocated towards healthcare. Furthermore, the government has been implementing reforms aimed at improving the efficiency of the healthcare system, which has led to increased access to healthcare services for Czech citizens.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.